Pfizer data ‘looks competitive’ to uniQure’s Hemgenix, says Wells Fargo

After Pfizer (PFE) announced top-line data from the Phase 3 BENEGENE-2 trial of gene therapy fidanacogene elaparvovec for the treatment of adult males with moderately severe to severe hemophilia B, Wells Fargo analyst Mohit Bansal said he thinks the data "looks competitive" when compared to uniQure’s (QURE) Hemgenix. Though Pfizer "may be 1-2 yrs behind the recently approved Hemgenix," he thinks Pfizer’s "commercial firepower could be helpful in catching up," added Bansal, who has an Overweight rating and $54 price target on Pfizer shares.